Braemar Hotels & Resorts Stock (NYSE: BHR)

Braemar Hotels & Resorts Stock (NYSE:BHR), Trade Ideas

Braemar Hotels & Resorts

Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and Renaissance, among others.

Concept,Of,Several,Properties,In,A,City,Generating,Passive,Income

REIT

Real Estate

GIPR

ILPT

The 5 Best-Performing REITs Under $5

Hotel,Sign,With,Stars,,3d,Illustration

AINC

CLDT

Equity Fund Buys Hersha Hospitality Trust: Hotel REITs Go Wild

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

Bluerock Homes Trust, Inc. Class A Common Stock

RMAX

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.

Top 5 Real Estate Stocks That May Explode In August

Braemar Hotels & Resorts Inc. Common Stock

Braemar Hotels & Resorts Inc

Burke & Herbert Financial Services Corp. - Common Stock

Burke & Herbert Financial Services Corp

Braemar Hotels & Resorts Inc. 5.50% Series B Cumulative Convertible Preferred Stock, par value $0.01 per share

Braemar Hotels & Resorts Inc. 8.25% Series D Cumulative Preferred Stock, par value $0.01 per share

Jefferies analyst Blayne Curtis assumes Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy rating and raises Price Target to $1100.

Price Target

Initiation

Analyst Ratings

LRCX

Jefferies Assumes Lam Research at Buy, Raises Price Target to $1100

New Hybrid Solution Empowers Customers to Combine Existing Avaya Investments with Enhanced Collaboration Capabilities from RingCentral
RingCentral Enhances Avaya Cloud Office with RingSense AI and Microsoft Teams Integration
Today at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Favaya-engage.avaya.com%2Fdenver-2024%3FCTA%3D24CORP-EV-ENGAGE%26TAC%3D24CORP-EV-ENGAGE-SEM%26utm_campaign%3Dengage24%26cid%3D20990445514%26gad_source%3D1%26gclid%3DCjwKCAjww_iwBhApEiwAuG6ccCmYUz7tSlbChuW-ApEMHazoXDWzhD_G7GwmuOpVSRp1SGNUNjiMrxoCFVIQAvD_BwE&amp;esheet=53984250&amp;newsitemid=20240513262792&amp;lan=en-US&amp;anchor=Avaya+ENGAGE&amp;index=1&amp;md5=1d9bb04e3dfda6a01f6496d3d07e3a60">Avaya ENGAGE</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ringcentral.com&amp;esheet=53984250&amp;newsitemid=20240513262792&amp;lan=en-US&amp;anchor=RingCentral%2C+Inc.+%28NYSE%3A+RNG%29&amp;index=2&amp;md5=55108c65199410e2a997a984fc49a094">RingCentral, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>), a leading provider of AI-driven cloud business communications, contact center, video and hybrid event solutions, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avaya.com%2Fen%2F&amp;esheet=53984250&amp;newsitemid=20240513262792&amp;lan=en-US&amp;anchor=Avaya&amp;index=3&amp;md5=081a223fdecd37e388a3b75dd8e2497b">Avaya</a>, a global leader in customer experience and communications solutions, announced an expansion of offerings for Avaya customers, including a new hybrid solution of RingCentral's AI-powered cloud business communications solution with Avaya Aura telephony, providing enhanced collaboration capabilities.

Avaya And RingCentral Expand Partnership With AI-Powered Communications And Collaboration Experiences

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 23.53 percent increase over losses of $(0.68) per share from the same period last year.

Earnings

Earnings Beats

IMNN

Imunon Q1 EPS $(0.52) Beats $(0.57) Estimate

IMNM

CORRECTION: Immunome Did Not Report Q1 Earnings On May 13, 2024

Truist Securities analyst Mark Hughes maintains Main Street Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIN#NYSE">MAIN</a>) with a Hold and raises the price target from $45 to $52.

MAIN

Truist Securities Maintains Hold on Main Street Capital, Raises Price Target to $52

<ul>
<li>Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody.</li>
</ul>

MRUS

Petosemtamab Receives Breakthrough Therapy Designation From FDA

Jefferies analyst Blayne Curtis assumes Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Hold rating and lowers Price Target of $34.

INTC

Jefferies Assumes Intel at Hold, Lowers Price Target of $34

XBP Europe Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) reported quarterly losses of $(0.07) per share. This is a 36.36 percent increase over losses of $(0.11) per share from the same period last year. The company reported $40.28 million in sales this quarter. This is a 5.83 percent decrease over sales of $42.78 million the same period last year.

XBP Europe Holdings Q1 EPS $(0.07) Up From $(0.11) YoY, Sales $40.28M Down From $42.78M YoY

Wedbush analyst Daniel Ives reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and maintains $250 price target.

Reiteration

AAPL

Wedbush Reiterates Outperform on Apple, Maintains $250 Price Target

Truist Securities analyst Jake Bartlett maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Hold and lowers the price target from $68 to $60.

CBRL

Truist Securities Maintains Hold on Cracker Barrel Old, Lowers Price Target to $60

Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year.

CMPX

Compass Therapeutics Q1 EPS $(0.08) Beats $(0.11) Estimate

Health Care

General

BMRA

Biomerica Announces inFoods Pilot Launch With An 1,000-Member Physician Group

Biotech

FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Wedbush analyst Richard Anderson reiterates UMH Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>) with a Neutral and maintains $17 price target.

Wedbush Reiterates Neutral on UMH Properties, Maintains $17 Price Target

Treasure Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) ("Treasure Global" or the "Company"), an innovative technology solutions provider, has announced its emergence as the exclusive partner for an AI Blockchain Wallet on Telegram, marking a significant stride in the blockchain industry. &nbsp;
Originating from a Poland licensed blockchain company, this AI Blockchain Wallet revolutionizes decentralized transactions. It allows users to seamlessly perform transfers, deposits, coin swaps, cross-chain operations, and staking, all through a user-friendly one-button application on Telegram.

Treasure Global Picked As Exclusive Partner For AI Blockchain Wallet On Telegram

Jefferies analyst Blayne Curtis maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and lowers the price target from $200 to $190.

Jefferies Maintains Buy on Advanced Micro Devices, Lowers Price Target to $190

Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 16.67 percent increase over losses of $(0.48) per share from the same period last year.

BRNS

Barinthus Biotherapeutics Q1 EPS $(0.40) Beats $(0.54) Estimate

<a href="https://www.globenewswire.com/Tracker?data=E3eR7rFz71jhu1nSaA51uy90fg0hcYIex9wYv6QGtQ53eukxnK3huuMVCFOkTe-RHmVHjG0tBO6mv5sSG1ht2A==">IN8bio</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene &amp; Cell Therapy (ASGCT) 2024 Annual Meeting. &nbsp;
In an oral presentation titled: "Healthy Donor vs. Patient Manufactured Autologous DeltEx DRI Product; Immunophenotyping Gene Expression," IN8bio provided novel characterization data demonstrating the reproducibility and robust cellular properties of its clinical-scale manufactured investigational products. These data demonstrate that the manufacturing process results in investigational products with upregulated markers of potency, effector functions and trafficking capabilities, which IN8bio believes represents a significant advancement in the characterization of gamma-delta T cell-based therapies.

INAB

IN8bio Showcases Reproducible Gamma-Delta T Cell Therapy Manufacturing In Oral Presentation At ASGCT 2024

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $8 to $7.

CHRS

Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

BNTC

Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY

Higher For Longer? Focus On The Balance Sheet

Real estate stocks finish in green as analysts turn positive, earnings surprise to upside

Warning: BHR is at high risk of performing badly

Braemar Hotels & Resorts Q1 Earnings Preview

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Braemar Hotels &amp; Resorts (NYSE:<a href="https://investorplace.com/stock-quotes/bhr-stock-quote/">BHR</a>) just reported results for the first quarter of 2024.<ul><li>Braemar Hotels &amp; Resorts reported earnings per share of 42 cents.</li><li>The company reported revenue of $219.08 million.</li><li>This was 3.99% better than the analyst estimate for revenue of $210.68 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bhr-stock-earnings-braemar-hotels-resorts-for-q1-of-2024/">BHR Stock Earnings: Braemar Hotels &amp; Resorts Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BHR Stock Earnings: Braemar Hotels & Resorts Beats Revenue for Q1 2024

Braemar Hotels &amp; Resorts FFO of $0.42 beats by $0.07, revenue of $219.08M beats by $8.4M

Braemar Hotels & Resorts Inc. (BHR) Q1 2024 Earnings Call Transcript

An update from Braemar Hotels & Resorts Inc (BHR) is now available. Braemar Hotels & Resorts Inc. conducted a conference call on May 9, 2024, to di...

Braemar Hotels Reviews Q1 Financial Performance

In a report released on May 8, Michael Bellisario from Robert W. Baird maintained a Hold rating on Braemar Hotels & Resorts (BHR – Research Report)...

Braemar Hotels & Resorts: Balancing Earnings Success and Strategic Initiatives Against Governance Concerns

Braemar Hotels & Resorts (BHR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Braemar Hotels & Resorts is grappling wi...

Braemar Hotels Struggles Against Activist Shareholders: A Costly Battle Impacting Business Health

AGNC

AIRE

ASPS

BBRE

BEKE

CBRE

CSGP

DFAR

EPRT

EQIX

ESRT

FREL

HOUS

INDS

INVH

JPRE

KBWY

MORT

NETL

NURE

OPEN

PPTY

RIET

ROOF

RSPR

SBAC

SCHH

SPRE

SRET

SRVR

STAG

USRT

VICI

WELL

XLRE

Press Releases

BRAEMAR HOTELS & RESORTS COMPLETES NEW FINANCING FOR THE RITZ-CARLTON RESERVE DORADO BEACH

BRAEMAR HOTELS & RESORTS ANNOUNCES REJECTION OF MATERIALLY DEFICIENT DIRECTOR NOMINATION NOTICE FROM BLACKWELLS CAPITAL

BRAEMAR HOTELS & RESORTS SETS FIRST QUARTER EARNINGS RELEASE AND CONFERENCE CALL DATES

Blackwells Files Definitive Proxy Statement for Braemar Hotels & Resorts Inc.'s 2024 Annual Meeting

Dividends

BRAEMAR HOTELS & RESORTS DECLARES DIVIDENDS FOR THE SECOND QUARTER OF 2024

BRAEMAR HOTELS & RESORTS REMINDS SHAREHOLDERS TO DISREGARD BLACKWELLS CAPITAL'S UNLAWFUL PROXY MATERIALS

Management

Blackwells Releases Letter to Fellow Braemar Hotels & Resorts Inc.'s Shareholders

BRAEMAR HOTELS & RESORTS ANNOUNCES SHAREHOLDER VALUE CREATION PLAN

Blackwells Comments on Braemar's Too Little Too Late Shareholder Value Creation "Plan"

Blackwells Exposes the Futility of Braemar's May 6th Announcement

Ashford Hospitality Trust Inc Common Stock

Ashford Hospitality Trust

Apple Hospitality REIT, Inc. Common Shares

Apple Hospitality REIT

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging

Diamondrock Hospitality Company Common Stock

Diamondrock Hospitality

Host Hotels & Resorts, Inc. - Common Stock

Host Hotels & Resorts

InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality

Summit Hotel Properties, Inc. Common Stock

Summit Hotel Properties

Pebblebrook Hotel Trust Common Shares of Beneficial Interest

Pebblebrook Hotel

Park Hotels & Resorts

Ryman Hospitality Properties, Inc. (REIT)

Ryman Hospitality Props

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

RLJ Lodging

Sunstone Hotel Investors, Inc. Sunstone Hotel Investors, Inc. Common Shares

Sunstone Hotel Invts

Sotherly Hotels

Service Properties Trust - Shares of Beneficial Interest

Service Properties Trust

Xenia Hotels & Resorts, Inc. Common Stock